Barclays lowered the firm’s price target on Beam Therapeutics to $33 from $42 and keeps an Equal Weight rating on the shares. The company’s Q1 was largely inline and its clinical pipeline development was on track, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
- Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call
- Beam Therapeutics Stock (NASDAQ:BEAM): Investing in Cutting-Edge Gene Editing
- Citi sees limited readthrough for Beam Therapeutics from VERVE-101 trial pause
- Is Beam Therapeutics (NASDAQ:BEAM) Too Late to the Game?